Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparative double-blind controlled for the effect of fenofibrate treatment on the expression of genes of cholesterol homeostasis, inflammation and cell proliferation in carotid plaques asymptomatic arteriosclerosis. [Etude controlee comparative en double aveugle de l'effet d'un traitement par le fenofibrate sur l'expression des genes de l'homeostasie du cholesterol, de l'inflammation et de la proliferation cellulaire dans les plaques arterosclereuses carotidiennes asymptomatiques.]

Trial Profile

A comparative double-blind controlled for the effect of fenofibrate treatment on the expression of genes of cholesterol homeostasis, inflammation and cell proliferation in carotid plaques asymptomatic arteriosclerosis. [Etude controlee comparative en double aveugle de l'effet d'un traitement par le fenofibrate sur l'expression des genes de l'homeostasie du cholesterol, de l'inflammation et de la proliferation cellulaire dans les plaques arterosclereuses carotidiennes asymptomatiques.]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fenofibrate (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms FENOGEN
  • Most Recent Events

    • 29 Aug 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top